Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.
Hadeel HalalshehMary Beth McCarvilleMichael NeelMark ReynoldsMichael C CoxAlberto S PappoPublished in: Pediatric blood & cancer (2018)
Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6-NTRK fusion, which constitutively activates the tropomyosin-related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity in adult and pediatric patients who have TRK fusions. We present a rare case of a patient with mesoblastic nephroma metastatic to bone who had a dramatic response to larotrectinib.
Keyphrases
- rare case
- bone mineral density
- signaling pathway
- case report
- soft tissue
- bone loss
- squamous cell carcinoma
- bone regeneration
- small cell lung cancer
- acute lymphoblastic leukemia
- postmenopausal women
- epithelial mesenchymal transition
- body composition
- oxidative stress
- preterm infants
- young adults
- induced apoptosis
- protein kinase